Senseye

Senseye enables early detection, diagnosis and management of mental health conditions using breakthrough digital biomarkers, facilitating measurement based care both in mental healthcare and collaborative care settings. Senseye's diagnostic platform (Senseye Dx) asks patients to look at the screen of their mobile phone and perform simple ocular tasks while Senseye measures their eyes' response to stimuli. Senseye then provides their clinician with a binary differential diagnosis for PTSD, MDD, and GAD as well as a severity score. Senseye leverages machine learning and computer vision technologies to operationalize science that has been well established for decades. For the first time, patients and clinicians have access to an accurate, objective measure of the patient's condition during treatment.

Mental Health conditions affect 1 in 4 globally, and the global spend to treat these conditions is over $400 billion - without any objective way to measure the conditions or the efficacy of the treatments. There are also a large numbers of misdiagnosis or no diagnosis due to subjective self reporting. Misdiagnosis rates are 65.9% for major depressive disorder, 80.5% for PTSD and 71.0% for generalized anxiety disorder. For some conditions, such as PTSD, trauma disclosure is required to receive a diagnosis under DSM5 criteria - studies show that the average time from trauma to disclosure to a mental health professional is 7-10 years. During this period patients are often treated for symptoms of their PTSD rather than the underlying condition leading to worsening and sometimes devastating mental and physical health outcomes. Senseye's regulated diagnostic platform aims to replace the standard questionnaires for diagnosing PTSD, MDD, and GAD, and is the first regulated mental health diagnostic that the FDA is considering for approval. Senseye helps diagnose PTSD without requiring trauma disclosure, reducing the stigma associated with seeking mental health care. It provides signals that can be used to make clinical decisions, by quickly identifying patients facing mental health issues to intervene before suicidal thoughts occur, without requiring trauma disclosure, and assisting in determining treatment effectivity. Moving to measurement based care has the potential to decrease healthcare costs by 65% - 90% and help reduce the estimated $1trillion p.a. productivity losses to anxiety and depressive disorders.

Senseye has interfaced with pharmaceutical companies, payers, the VA, patients, telehealth companies and numerous clinicians including experts in the field of psychiatry. We look forward to continuing to work with all of these stakeholders, but we have had the most impact so far in our partnerships with customers and potential customers at pharmaceutical and telehealth companies. Both of these groups are enthusiastic about using the Senseye diagnostic to improve their own ability to reach and support patients with mental health issues. Pharmaceutical companies by working with Senseye as an endpoint on a clinical trial, and telehealth by planning to implement the Senseye diagnostic into their workflow and add time saving and value to patients and clinicians.